We are committed to making our drugs affordable and available to the broadest possible population. Our first project was to create and test a new AIDS drug. If it proves successful, ongoing use of this drug will restore and maintain health in an HIV-positive person indefinitely. In addition, we are developing a pipeline of treatments for autoimmune diseases such as juvenile-onset diabetes and rheumatoid arthritis. They have been very effective for some, but not at all effective for others.
Experts agree that new approaches to research and treatment are necessary.
AIDS researchers from around the world are pointing to the importance of manipulating the human immune system, rather than attacking the virus, as the new approach to AIDS treatment. Furthermore, we expect our treatment could allow even people with advanced AIDS to recover fully. Our drug could be used for the growing number of people living with drug-resistant strains of the virus. We believe it will be practical for many of the people, health-service providers, and governments who are unable to afford or to manage current AIDS treatments. Pilot Testing and Review Pilot tests of Immudel-gp120 have shown two things.